The Cancer Moonshot launched in 2016 with $1.8 billion in federal funding and a bold promise: compress a decade of cancer research progress into five years. It was reignited in 2022 with an even bigger target, cutting the U.S. cancer death rate in half over 25 years. The initiative has funded real research, spun up new programs, and contributed to steady declines in cancer mortality, but it hasn’t produced the single dramatic breakthrough its name implies. Here’s where things actually stand.
How the Moonshot Started
President Obama announced the Cancer Moonshot in his 2016 State of the Union address and put then-Vice President Joe Biden in charge. Biden’s personal connection to the effort was well known: his son Beau had died of brain cancer in 2015. Later that year, the 21st Century Cures Act authorized $1.8 billion over seven years to fund the initiative through the National Cancer Institute.
An expert panel issued 12 broad recommendations that shaped the program’s direction. The priorities included accelerating clinical trials, improving data sharing across research institutions, expanding access to genomic profiling of tumors, and building collaborations between government, academia, and the private sector. The NCI used those recommendations to set concrete research goals spanning prevention, screening, diagnosis, and treatment.
The 2022 Relaunch
When Biden became president, he reignited the Moonshot in February 2022 with a more ambitious target: cut the cancer death rate in half within 25 years. The relaunch also included a call to action on cancer screening, specifically to recover the millions of screenings missed during the COVID-19 pandemic. The framing shifted slightly, with greater emphasis on prevention, health equity, and the patient experience alongside the original research agenda.
Where Cancer Death Rates Stand Now
Cancer death rates have been falling steadily, though not at the pace needed to hit that 50% reduction goal on schedule. From 2018 to 2022, cancer deaths dropped an average of 1.7% per year for men and 1.3% per year for women. At that rate, it would take roughly 30 to 40 years to halve the death rate, not 25.
Some cancers are moving faster than others. Lung cancer deaths fell the fastest, dropping 4.5% per year for men and 3.4% per year for women over that same period, driven largely by declining smoking rates and newer targeted therapies. Breast cancer deaths have fallen 42% from their 1989 peak. Childhood cancer deaths have decreased about 1.5% per year since 2001. But several cancer types, particularly pancreatic and liver cancers, have been far more stubborn.
These trends started well before the Moonshot existed, which makes it hard to credit the initiative with the overall decline. The Moonshot’s real contribution is in laying groundwork that could accelerate these curves in the years ahead.
What the Funding Actually Built
The Moonshot’s most tangible outputs are research programs and infrastructure rather than single headline-grabbing cures. One significant effort is the Childhood Cancer Data Initiative, which focuses on connecting pediatric cancer data across hospitals and registries nationwide. By linking treatment records, genomic profiles, and long-term outcomes, the program aims to identify new therapeutic targets, especially for rare childhood cancers where no standard treatment exists. A national childhood cancer registry now covers about 70% of the U.S. pediatric cancer population, with expansion to 80% expected as more states join. The initiative’s Molecular Characterization Initiative provides free tumor genomic sequencing for children treated at institutions that lack the resources or funding for such testing.
The broader Moonshot portfolio also supported work on immunotherapy combinations, cancer vaccine development, and better understanding of how cancers resist treatment. Much of this research is still in progress. Cancer research timelines are long. A promising finding in 2018 might only reach patients in clinical trials by 2025 and standard care years after that.
ARPA-H and New Technology Bets
The Advanced Research Projects Agency for Health, created in 2022, has become a parallel track for high-risk cancer research aligned with Moonshot goals. ARPA-H funds projects that traditional research grants typically won’t touch because they’re too ambitious or unconventional.
Three active projects illustrate the approach. One is developing a low-cost breast MRI device designed to work outside major radiology centers, making screening accessible in smaller clinics and rural areas. Another, called the Cancer and Organ Degradome Atlas, uses synthetic biology to build sensors that could be deployed inside the body to detect malignant cells. A third project aims to reprogram immune cells directly using RNA-based techniques to fight cancers that don’t respond to existing immunotherapies. None of these are available to patients yet, but they represent the kind of longer-term, higher-ceiling bets the Moonshot ecosystem is designed to support.
Environmental Cancer Prevention
One underreported piece of the Moonshot has been a push to reduce cancer-causing chemical exposures. The EPA launched several regulatory actions tied to Moonshot goals. Proposed rules targeted industrial chemicals like trichloroethylene (a degreasing solvent linked to multiple cancers), perchloroethylene (used in dry cleaning, linked to liver and kidney cancer), and methylene chloride. The agency also proposed the first-ever enforceable drinking water limits for six PFAS compounds, two of which are classified as carcinogens.
A separate proposal to cut emissions from chemical plants manufacturing ethylene oxide and chloroprene would eliminate more than 6,000 tons of toxic air pollution annually, reducing cancer risk in surrounding communities that have historically borne the heaviest burden of industrial pollution. These regulatory actions represent a prevention-first approach that complements the research side of the Moonshot, though many of these proposed rules face lengthy implementation timelines and potential legal challenges.
What Changed Under the Trump Administration
The Moonshot’s future shifted significantly after the 2024 presidential election. The initiative was closely identified with Biden personally, and the incoming Trump administration signaled different priorities for federal health spending. ARPA-H faced proposed budget cuts, and several Biden-era health equity programs were scaled back or restructured. The core NCI research funded through the 21st Century Cures Act had already been largely disbursed by the time the original seven-year authorization window was closing, so many funded studies continue regardless of political changes. But the coordinating infrastructure, the White House cancer cabinet, the interagency alignment, and the political momentum behind the initiative have largely dissolved.
The research doesn’t disappear when the branding does. Scientists working on Moonshot-funded projects continue their work through existing grants. Data systems like the childhood cancer registry keep operating. But the initiative’s ability to launch new large-scale programs and drive cross-agency coordination depends on sustained political will, and that is no longer guaranteed.
Did the Moonshot Deliver?
If you expected a single breakthrough that “cured cancer,” the Moonshot hasn’t delivered that, and it was never realistic to expect it would. Cancer is hundreds of different diseases, each with distinct biology. What the Moonshot did accomplish was meaningful but incremental: better data infrastructure, expanded access to genomic testing for underserved patients, new collaborative research networks, and regulatory action on environmental carcinogens.
The 50% mortality reduction goal remains technically achievable but would require acceleration beyond current trends. The most promising paths forward, including blood-based multi-cancer screening tests, personalized cancer vaccines, and next-generation immunotherapies, are all in various stages of development, some with Moonshot funding behind them. Whether those advances arrive fast enough to meet the 2047 target depends less on any single government initiative and more on sustained investment across public and private research over the next two decades.